Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery

Inclusion Criteria: * Male or non-pregnant, non-lactating female patients of any race in the ages of \>18 years. * Patients scheduled for combined aortic valve replacement and CABG surgery. * Patients who have given written informed consent prior to participation in the trial and who undertake to comply with the protocol. Exclusion Criteria: * Patients who are unwilling or unable to be fully evaluated for follow-up. * Patients who have base AP levels at \> 125 IU/L, or levels \< 30 IU/L (ammediol, DEA (diethanolamine) units) * Patients who show pre-operative infections or who are suspected of endocarditis or systemic infection. * Patients who refuse to accept medically-indicated blood products. * Patients who have evidence of significant hepatic disease, including history of clinical signs or laboratory values of total bilirubin \> 34.2 µmol/L (\> 2.0 mg/dL), ALT (\>120) or AST (\>135) corresponding to \> 3X upper limit of normal. * Patients who received investigational drugs in the 30 days prior to study drug administration, or are currently participating in a study during which the administration of investigational drugs within one month is anticipated. * Patients who require pre-operative ventilatory support. * Patients who have renal insufficiency (history of creatinine \>177mol/L or \>2.0 mg/dL) or chronic renal failure requiring dialysis. * Patients who are planned to receive leukocyte-depletion filtration as part of the bypass circuitry. * Patients with severe neuro…